Mar 30 2007, 6:03 AM EST
MARKETWIRE
Mar 30, 2007 LONDON, ONTARIO MARKET WIRE
Critical Outcome Technologies Inc. (TSX VENTURE: COT), provided an update to the market today on its Multiple Sclerosis (MS) Library.
Critical Outcome Technologies Inc. (COTI) has been monitoring the synthesis of its first four MS compounds through regular meetings with its synthetic chemistry partner, Dalton Pharma Services (Dalton). "The COTI MS compounds are novel and therefore have not been made before. Each of the first four COTI MS compounds has required the research and development of some entirely new chemistry. As a result, this new chemistry will strengthen our patent position and add to the value realized by future customers" said Dr. Wayne Danter, President and Chief Scientific Officer of COTI.
Dalton has manufactured small amounts of the lead MS compound COT601-M06.1, but has encountered difficulty with scaling up production. Dalton will continue its work synthesizing the lead MS compound COT601-M06.1 and is confident that they will be successful in scaling up production.
Since the November 2006 start of the MS molecule synthesis, COTI has broadened its synthetic chemistry resource base in recognition of the complexity and issues surrounding compounds requiring new chemistry. Delmar Chemicals (Delmar)of Montreal has consulted since February 2007 to synthesize the second two MS compounds starting with the lead MS compound COT604-M06.2. Delmaris also confident that hey will be successful in scaling up production.
"COTI together with our synthetic chemistry partners remain confident that these novel compounds will be successfully synthesized in the near future" said Dr. Wayne Danter. "We will continue our pursuit of seeking an effective treatment for acute MS and we will remain focused on engaging prospective partners and customers with this library of novel, optimized lead compounds."
About Critical Outcome Technologies Inc.
COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for the accelerated identification, profiling and optimization n of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CSO
(519) 858-5157
Email: wdanter@criticaloutcome.com
Critical Outcome Technologies Inc.
Michael Barr
Director of Marketing & Business Development
(519) 858-5157
Email: mbarr@criticaloutcome.com
Website: www.criticaloutcome.com
SOURCE: Critical Outcome Technologies Inc.
